Ancillary Educational Events

III, II, I: Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy—Cutting-Edge Research, Clinical Applications, and Practical Challenges

Date and Time: Thursday, February 28, 7:30 PM (Dinner and registration at 7:00 PM)

Location: Park Central Hotel San Francisco, Metropolitan I & II

CME Provider and Supporter(s): This event is organized by PVI, PeerView Institute for Medical Education, accredited by Medical Learning Institute, Inc., and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: To register for the event, visit: PeerView.com/SF19Lung. For additional information, email margaret.bravo@peerview.com or call 1-877-833-6141.

EVENT SUMMARY

The standard of care in stage III locally advanced unresectable non–small cell lung cancer (NSCLC) has changed with the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. Immunotherapies are also showing promise in earlier stages of lung cancer. How should immunotherapy be integrated into the management of patients with stage III NSCLC? What are the practical nuances of use that should be considered, including timing and duration of therapy, and management of overlapping and nonoverlapping adverse effects? What immunotherapy-based rational treatment approaches are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer? Answers to these key questions and others will be provided in this comprehensive educational event comprising didactic seminars and a practical “how I think, how I treat” session delivered by leading experts in the field.

FACULTY

Scott J. Antonia, MD, PhD
Duke Cancer Institute

Roy H. Decker, MD, PhD
Yale School of Medicine

Edward S. Garon, MD, MS
UCLA's Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA

New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations

Date and Time: Friday, March 1, 7:30 PM (Dinner and registration at 7:00 PM)

Location: Park Central Hotel San Francisco, Metropolitan I & II

CME Provider and Supporter(s): This event is organized by PVI, PeerView Institute for Medical Education, accredited by Medical Learning Institute, Inc., and is supported by educational grants provided by Bristol-Myers Squibb, Incyte Corporation, Foundation Medicine, Inc., and Merck & Co., Inc.

Registration and Contact Information: To register for the event, visit: PeerView.com/Precision19. For additional information, email margaret.bravo@peerview.com or call 1-877-833-6141.

EVENT SUMMARY

As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. Which immune-based agents or combinatorial approaches can provide the most benefit to individual patients with different malignancies? Which factors should be considered in determining the right treatment for the right patient at the right time? And which current and emerging biomarkers (eg, PD-L1, MSI/MMR, TMB, etc.) have clinical utility, and how can they be used to refine and expand the use of current and emerging immunotherapy options and combinations? How can we make the most of the latest scientific, clinical, and technological advances to further facilitate progress in the area of precision immuno-oncology? Please join our educational session to hear the latest on the present and future of cancer immunotherapies and biomarkers, debate critical issues and questions with a panel of experts, and get practical guidance that you can use in the care of your patients with cancer. 

FACULTY

Justin F. Gainor, MD
Massachusetts General Hospital

Edward S. Garon
UCLA's Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA

Kurt Schalper, MD, PhD
Yale School of Medicine, Yale Cancer Center